Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.42 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.40 |
| ▸ | HINT1 | P49773 | 3/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21474246 | 0.92 | POLB (0.46) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL21489208 | 0.91 | KDM4E (0.39) | POLBP2RY2P2RY4P2RY6KDM4E | |
| SCHEMBL21489386 | 0.88 | POLB (0.48) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL4578872 | 0.87 | POLB (0.51) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL1514931 | 0.87 | POLB (0.51) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL12570242 | 0.87 | POLB (0.51) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL16844109 | 0.87 | POLB (0.51) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL7613803 | 0.87 | POLB (0.51) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL4579548 | 0.85 | POLB (0.49) | POLBP2RY2P2RY4P2RY6FUT5 | |
| SCHEMBL4579553 | 0.85 | POLB (0.49) | POLBP2RY2P2RY4P2RY6FUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE | 2023-08-03 | — | — | US | disclosed |
| US-11613554-B2 | Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-03-28 | — | — | US | disclosed |
| US-20190322694-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, INPP5B, PTMS | POLB 1692/4885P2RY2 736/4885P2RY4 293/4885 |
| US-11613554-B2 | Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds | PPIP5K2, INPP5B, PTMS | POLB 1692/4885P2RY2 736/4885P2RY4 293/4885 |
| US-20190322694-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, INPP5B, PTMS | POLB 2210/4885P2RY2 613/4885P2RY4 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.